Evercore ISI initiated coverage on shares of Akero Therapeutics (NASDAQ:AKRO) in a report released on Monday morning, Briefing.com Automated Import reports. The firm issued an outperform rating and a $35.00 target price on the stock.

AKRO has been the subject of a number of other research reports. Jefferies Financial Group set a $189.00 price objective on shares of salesforce.com and gave the company a buy rating in a report on Monday. Roth Capital restated a buy rating on shares of Coeur Mining in a report on Monday. Finally, JPMorgan Chase & Co. restated a sell rating and set a $18.00 price objective on shares of ABB in a report on Monday.

Shares of NASDAQ AKRO opened at $21.55 on Monday. Akero Therapeutics has a 52-week low of $16.06 and a 52-week high of $21.94.

In related news, Director Seth Loring Harrison purchased 900,000 shares of the business’s stock in a transaction on Monday, June 24th. The shares were purchased at an average price of $16.00 per share, with a total value of $14,400,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Global Strategic Fund I. Venbio purchased 250,000 shares of the business’s stock in a transaction on Monday, June 24th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $4,000,000.00. The disclosure for this purchase can be found here.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Recommended Story: How to Trade Using Analysts Ratings

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.